Advertisement

Insulin Resistance and the Metabolic Syndrome

  • Mary Ann BanerjiEmail author
  • Milay Luis LamEmail author
  • Rochelle Chaiken
Reference work entry

Abstract

In 1988 Gerald Reaven’s Banting Lecture popularized the metabolic syndrome and proposed that insulin resistance was the underlying etiology of a set of abnormalities including glucose intolerance, hypertension, and a distinct lipid profile of high triglyceride and low HDL cholesterol level with resultant increased cardiovascular disease and diabetes. This physiological concept evolved into an epidemiological one used to predict cardiovascular disease and diabetes. Following multiple definitions by self-appointed organizations, in 2009 an international group of experts proposed a “harmonized” definition of the metabolic syndrome. This definition included a population-specific measure of waist circumference, elevated plasma triglyceride, low plasma HDL cholesterol, hypertension, and elevated blood glucose. The metabolic syndrome has been tested in numerous large, longitudinal population studies to determine its ability to predict cardiovascular disease above and beyond its individual components.

The evidence is mixed and suggests that metabolic syndrome does not uniquely predict incident CV disease or mortality over and above its components. Despite positive reports, overall, the metabolic syndrome is a rather poor predictor of CV disease in type 2 diabetes.

The metabolic syndrome is likely to be not more than the sum of its parts after adjusting for standard CV risk factors. Although it is a good predictor of diabetes, it is not as good as the fasting plasma glucose.

Keywords

Insulin resistance Metabolic syndrome Healthy/unhealthy obesity Cardiovascular disease Mortality and diabetes Glucose intolerance Plasma triglyceride Plasma HDL cholesterol body composition Visceral fat 

References

  1. 1.
    Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am. 2004;33(2):283–303.PubMedCrossRefGoogle Scholar
  2. 2.
    Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–95.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest. 2002;32 Suppl 3:35–45.PubMedCrossRefGoogle Scholar
  4. 4.
    Taguchi A, White MF. Insulin-like signaling, nutrient homeostasis, and life span. Annu Rev Physiol. 2008;70:191–212.PubMedCrossRefGoogle Scholar
  5. 5.
    Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85–96.PubMedCrossRefGoogle Scholar
  6. 6.
    Chen Y, Zhu J, Lum PY, et al. Variations in DNA elucidate molecular networks that cause disease. Nature. 2008;452(7186):429–35.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Muoio DM, Newgard CB. Mechanisms of disease: Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(3):193–205.PubMedCrossRefGoogle Scholar
  8. 8.
    Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–607.PubMedCrossRefGoogle Scholar
  9. 9.
    Lebovitz HE. Insulin resistance – a common link between type 2 diabetes and cardiovascular disease. Diabetes Obes Metab. 2006;8(3):237–49.PubMedCrossRefGoogle Scholar
  10. 10.
    Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest. 2000;105(3):311–20.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Schwartz EA, Reaven PD. Molecular and signaling mechanisms of atherosclerosis in insulin resistance. Endocrinol Metab Clin North Am. 2006;35(3):525–49. viii.PubMedCrossRefGoogle Scholar
  12. 12.
    Fröjdö S, Vidal H, Pirola L. Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans. Biochim Biophys Acta. 2009;1792(2):83–92.PubMedCrossRefGoogle Scholar
  13. 13.
    Leroith D, Accili D. Mechanisms of disease: using genetically altered mice to study concepts of type 2 diabetes. Nat Clin Pract Endocrinol Metab. 2008;4(3):164–72.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214–23.PubMedGoogle Scholar
  15. 15.
    Sherwin RS, Kramer KJ, Tobin JD, et al. A model of the kinetics of insulin in man. J Clin Invest. 1974;53(5):1481–92.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Shen SW, Reaven GM, Farquhar JW. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest. 1970;49(12):2151–60.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest. 1981;68(6):1456–67.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest. 1987;79(3):790–800.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol. 1979;236(6):E667–77.PubMedGoogle Scholar
  20. 20.
    Yang YJ, Youn JH, Bergman RN. Modified protocols improve insulin sensitivity estimation using the minimal model. Am J Physiol. 1987;253(6 Pt 1):E595–602.PubMedGoogle Scholar
  21. 21.
    Beard JC, Bergman RN, Ward WK, Porte D. The insulin sensitivity index in nondiabetic man. Correlation between clamp-derived and IVGTT-derived values. Diabetes. 1986;35(3):362–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Finegood DT, Hramiak IM, Dupre J. A modified protocol for estimation of insulin sensitivity with the minimal model of glucose kinetics in patients with insulin-dependent diabetes. J Clin Endocrinol Metab. 1990;70(6):1538–49.PubMedCrossRefGoogle Scholar
  23. 23.
    Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care. 2000;23(3):295–301.PubMedCrossRefGoogle Scholar
  24. 24.
    Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–70.PubMedCrossRefGoogle Scholar
  25. 25.
    Gutt M, Davis CL, Spitzer SB, et al. Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. Diabetes Res Clin Pract. 2000;47(3):177–84.PubMedCrossRefGoogle Scholar
  26. 26.
    Avignon A, Boegner C, Mariano-Goulart D, Colette C, Monnier L. Assessment of insulin sensitivity from plasma insulin and glucose in the fasting or post oral glucose-load state. Int J Obes Relat Metab Disord. 1999;23(5):512–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol. 1993;137(9):959–65.PubMedCrossRefGoogle Scholar
  28. 28.
    Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care. 2000;23(2):171–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Hanson RL, Pratley RE, Bogardus C, et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol. 2000;151(2):190–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402–10.PubMedCrossRefGoogle Scholar
  32. 32.
    Rabasa-Lhoret R, Bastard JP, Jan V, et al. Modified quantitative insulin sensitivity check index is better correlated to hyperinsulinemic glucose clamp than other fasting-based index of insulin sensitivity in different insulin-resistant states. J Clin Endocrinol Metab. 2003;88(10):4917–23.PubMedCrossRefGoogle Scholar
  33. 33.
    Burén J, Lindmark S, Renström F, Eriksson JW. In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo? Metabolism. 2003;52(2):239–45.PubMedCrossRefGoogle Scholar
  34. 34.
    Perseghin G, Caumo A, Caloni M, Testolin G, Luzi L. Incorporation of the fasting plasma FFA concentration into QUICKI improves its association with insulin sensitivity in nonobese individuals. J Clin Endocrinol Metab. 2001;86(10):4776–81.PubMedCrossRefGoogle Scholar
  35. 35.
    Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab. 2000;85(12):4426–33.PubMedGoogle Scholar
  36. 36.
    Finegood DT, Bergman RN, Vranic M. Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamps. Comparison of unlabeled and labeled exogenous glucose infusates. Diabetes. 1987;36(8):914–24.PubMedCrossRefGoogle Scholar
  37. 37.
    Hales CN, Randle PJ. Immunoassay of insulin with insulin-antibody precipitate. Biochem J. 1963;88:137–46.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Kahn CR, Roth J. Berson, Yalow, and the JCI: the agony and the ecstasy. J Clin Invest. 2004;114(8):1051–4.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev. 1998;19(4):477–90.PubMedCrossRefGoogle Scholar
  40. 40.
    Ginsberg H, Kimmerling G, Olefsky JM, Reaven GM. Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. J Clin Invest. 1975;55(3):454–61.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Gautier JF, Wilson C, Weyer C, et al. Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes. Diabetes. 2001;50(8):1828–33.PubMedCrossRefGoogle Scholar
  42. 42.
    Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990;113(12):909–15.PubMedCrossRefGoogle Scholar
  43. 43.
    Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med. 1993;329(27):1988–92.PubMedCrossRefGoogle Scholar
  44. 44.
    DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988;37(6):667–87.PubMedCrossRefGoogle Scholar
  45. 45.
    Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993;42(11):1663–72.PubMedCrossRefGoogle Scholar
  46. 46.
    Cnop M, Vidal J, Hull RL, et al. Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care. 2007;30(3):677–82.PubMedCrossRefGoogle Scholar
  47. 47.
    Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104(6):787–94.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24(1):89–94.PubMedCrossRefGoogle Scholar
  49. 49.
    Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Järvinen H. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension. 1997;30(5):1144–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Banerji MA, Lebovitz HE. Insulin-sensitive and insulin-resistant variants in NIDDM. Diabetes. 1989;38(6):784–92.PubMedCrossRefGoogle Scholar
  51. 51.
    Chaiken RL, Banerji MA, Pasmantier R, Huey H, Hirsch S, Lebovitz HE. Patterns of glucose and lipid abnormalities in black NIDDM subjects. Diabetes Care. 1991;14(11):1036–42.PubMedCrossRefGoogle Scholar
  52. 52.
    Lorenzo C, Wagenknecht LE, D'Agostino RB, Rewers MJ, Karter AJ, Haffner SM. Insulin resistance, beta-cell dysfunction, and conversion to type 2 diabetes in a multiethnic population: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2010;33(1):67–72.PubMedCrossRefGoogle Scholar
  53. 53.
    Banerji MA, Lebovitz HE. Coronary heart disease risk factor profiles in black patients with non-insulin-dependent diabetes mellitus: paradoxic patterns. Am J Med. 1991;91(1):51–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Banerji MA, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Does intra-abdominal adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive? Diabetes. 1995;44(2):141–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A. 2007;104(31):12587–94.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Banerji MA, Buckley MC, Chaiken RL, Gordon D, Lebovitz HE, Kral JG. Liver fat, serum triglycerides and visceral adipose tissue in insulin-sensitive and insulin-resistant black men with NIDDM. Int J Obes Relat Metab Disord. 1995;19(12):846–50.PubMedGoogle Scholar
  57. 57.
    Hwang JH, Stein DT, Barzilai N, et al. Increased intrahepatic triglyceride is associated with peripheral insulin resistance: in vivo MR imaging and spectroscopy studies. Am J Physiol Endocrinol Metab. 2007;293(6):E1663–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Stanforth PR, Jackson AS, Green JS, et al. Generalized abdominal visceral fat prediction models for black and white adults aged 17-65 y: the HERITAGE Family Study. Int J Obes Relat Metab Disord. 2004;28(7):925–32.PubMedCrossRefGoogle Scholar
  59. 59.
    Beasley LE, Koster A, Newman AB, et al. Inflammation and race and gender differences in computerized tomography-measured adipose depots. Obesity (Silver Spring). 2009;17(5):1062–9.CrossRefGoogle Scholar
  60. 60.
    Banerji MA, Lebowitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Relationship of visceral adipose tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol. 1997;273(2 Pt 1):E425–32.PubMedGoogle Scholar
  61. 61.
    Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes. 2006;55 Suppl 2:S9–15.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes. 2005;54(1):8–14.PubMedCrossRefGoogle Scholar
  63. 63.
    Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005;307(5708):384–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A. 2003;100(14):8466–71.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Szendroedi J, Roden M. Mitochondrial fitness and insulin sensitivity in humans. Diabetologia. 2008;51(12):2155–67.PubMedCrossRefGoogle Scholar
  66. 66.
    Taniguchi A, Fukushima M, Sakai M, et al. The role of the body mass index and triglyceride levels in identifying insulin-sensitive and insulin-resistant variants in Japanese non-insulin-dependent diabetic patients. Metabolism. 2000;49(8):1001–5.PubMedCrossRefGoogle Scholar
  67. 67.
    Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab. 1999;84(1):137–44.PubMedGoogle Scholar
  68. 68.
    Haffner SM, Mykkänen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101(9):975–80.PubMedCrossRefGoogle Scholar
  69. 69.
    Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359(20):2105–20.PubMedCrossRefGoogle Scholar
  70. 70.
    Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA. 2005;293(15):1861–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Weyer C, Yudkin JS, Stehouwer CD, Schalkwijk CG, Pratley RE, Tataranni PA. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis. 2002;161(1):233–42.PubMedCrossRefGoogle Scholar
  72. 72.
    Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes. 2002;51(6):1884–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res. 2001;9(7):414–7.PubMedCrossRefGoogle Scholar
  74. 74.
    Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793–801.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Salmenniemi U, Ruotsalainen E, Pihlajamäki J, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation. 2004;110(25):3842–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest. 2008;118(9):2992–3002.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996;97(11):2601–10.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113(15):1888–904.PubMedCrossRefGoogle Scholar
  79. 79.
    Qasim A, Mehta NN, Tadesse MG, et al. Adipokines, insulin resistance, and coronary artery calcification. J Am Coll Cardiol. 2008;52(3):231–6.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002;51(10):2944–50.PubMedCrossRefGoogle Scholar
  81. 81.
    Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab. 2003;88(6):2399–403.PubMedCrossRefGoogle Scholar
  82. 82.
    Saad MF, Lillioja S, Nyomba BL, et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med. 1991;324(11):733–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Vella CA, Burgos X, Ellis CJ, et al. Associations of insulin resistance with cardiovascular risk factors and inflammatory cytokines in normal-weight Hispanic women. Diabetes Care. 2013;36(5):1377–83.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr. 1956;4(1):20–34.PubMedGoogle Scholar
  85. 85.
    Hsu WC, Araneta MR, Kanaya AM, Chiang JL, Fujimoto W. BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Diabetes Care. 2015;38(1):150–8.PubMedCrossRefGoogle Scholar
  86. 86.
    Consultation WE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157–63.CrossRefGoogle Scholar
  87. 87.
    McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism. 2004;53(4):495–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Bogardus C, Lillioja S, Mott DM, Hollenbeck C, Reaven G. Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol. 1985;248(3 Pt 1):E286–91.PubMedGoogle Scholar
  89. 89.
    Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. Endocrinol Metab Clin North Am. 2008;37(3):581–601. vii-viii.PubMedCrossRefGoogle Scholar
  90. 90.
    McLaughlin T, Abbasi F, Lamendola C, Reaven G. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med. 2007;167(7):642–8.PubMedCrossRefGoogle Scholar
  91. 91.
    Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes. 1998;47(5):699–713.PubMedCrossRefGoogle Scholar
  92. 92.
    Aung K, Lorenzo C, Hinojosa MA, Haffner SM. Risk of developing diabetes and cardiovascular disease in metabolically unhealthy normal-weight and metabolically healthy obese individuals. J Clin Endocrinol Metab. 2014;99(2):462–8.PubMedCrossRefGoogle Scholar
  93. 93.
    Arnlöv J, Ingelsson E, Sundström J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation. 2010;121(2):230–6.PubMedCrossRefGoogle Scholar
  94. 94.
    Abdullah A, Wolfe R, Stoelwinder JU, et al. The number of years lived with obesity and the risk of all-cause and cause-specific mortality. Int J Epidemiol. 2011;40(4):985–96.PubMedCrossRefGoogle Scholar
  95. 95.
    McLaughlin T, Lamendola C, Liu A, Abbasi F. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol Metab. 2011;96(11):E1756–60.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Gavin KM, Cooper EE, Raymer DK, Hickner RC. Estradiol effects on subcutaneous adipose tissue lipolysis in premenopausal women are adipose tissue depot specific and treatment dependent. Am J Physiol Endocrinol Metab. 2013;304(11):E1167–74.PubMedCrossRefGoogle Scholar
  97. 97.
    Palmer BF, Clegg DJ. The sexual dimorphism of obesity. Mol Cell Endocrinol. 2015;402:113–9.PubMedCrossRefGoogle Scholar
  98. 98.
    Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes. 1997;46(10):1579–85.PubMedCrossRefGoogle Scholar
  99. 99.
    Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes. 1999;48(4):839–47.PubMedCrossRefGoogle Scholar
  100. 100.
    Lemieux S, Després JP, Moorjani S, et al. Are gender differences in cardiovascular disease risk factors explained by the level of visceral adipose tissue? Diabetologia. 1994;37(8):757–64.PubMedCrossRefGoogle Scholar
  101. 101.
    Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350(25):2549–57.PubMedCrossRefGoogle Scholar
  102. 102.
    Mohammed BS, Cohen S, Reeds D, Young VL, Klein S. Long-term effects of large-volume liposuction on metabolic risk factors for coronary heart disease. Obesity (Silver Spring). 2008;16(12):2648–51.CrossRefGoogle Scholar
  103. 103.
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–9.PubMedCrossRefGoogle Scholar
  104. 104.
    Weber RV, Buckley MC, Fried SK, Kral JG. Subcutaneous lipectomy causes a metabolic syndrome in hamsters. Am J Physiol Regul Integr Comp Physiol. 2000;279(3):R936–43.PubMedGoogle Scholar
  105. 105.
    Lundgren M, Burén J, Lindgren P, Myrnäs T, Ruge T, Eriksson JW. Sex- and depot-specific lipolysis regulation in human adipocytes: interplay between adrenergic stimulation and glucocorticoids. Horm Metab Res. 2008;40(12):854–60.PubMedCrossRefGoogle Scholar
  106. 106.
    Wajchenberg BL, Giannella-Neto D, da Silva ME, Santos RF. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res. 2002;34(11-12):616–21.PubMedCrossRefGoogle Scholar
  107. 107.
    Tomlinson JW, Finney J, Gay C, Hughes BA, Hughes SV, Stewart PM. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity. Diabetes. 2008;57(10):2652–60.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Pan DA, Lillioja S, Kriketos AD, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 1997;46(6):983–8.PubMedCrossRefGoogle Scholar
  109. 109.
    Esser N, L'homme L, De Roover A, et al. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia. 2013;56(11):2487–97.PubMedCrossRefGoogle Scholar
  110. 110.
    Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996;2(7):800–3.PubMedCrossRefGoogle Scholar
  111. 111.
    Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87–91.PubMedCrossRefGoogle Scholar
  112. 112.
    Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005;11(2):191–8.PubMedCrossRefGoogle Scholar
  113. 113.
    Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420(6913):333–6.PubMedCrossRefGoogle Scholar
  114. 114.
    Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004;306(5695):457–61.PubMedCrossRefGoogle Scholar
  115. 115.
    Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes. 2002;51(7):2005–11.PubMedCrossRefGoogle Scholar
  116. 116.
    Tripathy D, Mohanty P, Dhindsa S, et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes. 2003;52(12):2882–7.PubMedCrossRefGoogle Scholar
  117. 117.
    Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res. 2006;45(1):42–72.PubMedCrossRefGoogle Scholar
  118. 118.
    Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40(11):1286–92.PubMedCrossRefGoogle Scholar
  119. 119.
    Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7(8):941–6.PubMedCrossRefGoogle Scholar
  120. 120.
    Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev. 2006;27(7):762–78.PubMedCrossRefGoogle Scholar
  121. 121.
    Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111–9.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Chaudhuri A, Janicke D, Wilson MF, et al. Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation. 2004;109(7):849–54.PubMedCrossRefGoogle Scholar
  123. 123.
    Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31(2):289–94.PubMedCrossRefGoogle Scholar
  124. 124.
    Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 1997;100(5):1166–73.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008;168(15):1617–24.PubMedCrossRefGoogle Scholar
  126. 126.
    Goday A, Calvo E, Vázquez LA, et al. Prevalence and clinical characteristics of metabolically healthy obese individuals and other obese/non-obese metabolic phenotypes in a working population: results from the Icaria study. BMC Public Health. 2016;16(1):248.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168(15):1609–16.PubMedCrossRefGoogle Scholar
  128. 128.
    Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. Eur Heart J. 2015;36(9):551–9.PubMedCrossRefGoogle Scholar
  129. 129.
    Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241(19):2035–8.PubMedCrossRefGoogle Scholar
  130. 130.
    Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med. 2001;161(14):1717–23.PubMedCrossRefGoogle Scholar
  131. 131.
    Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73–8.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–32.PubMedCrossRefGoogle Scholar
  133. 133.
    Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab. 2001;86(8):3574–8.PubMedCrossRefGoogle Scholar
  134. 134.
    Nosadini R, Manzato E, Solini A, et al. Peripheral, rather than hepatic, insulin resistance and atherogenic lipoprotein phenotype predict cardiovascular complications in NIDDM. Eur J Clin Invest. 1994;24(4):258–66.PubMedCrossRefGoogle Scholar
  135. 135.
    Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care. 2002;25(7):1177–84.PubMedCrossRefGoogle Scholar
  136. 136.
    Robins SJ, Rubins HB, Faas FH, et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care. 2003;26(5):1513–7.PubMedCrossRefGoogle Scholar
  137. 137.
    Kuusisto J, Lempiäinen P, Mykkänen L, Laakso M. Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. Diabetes Care. 2001;24(9):1629–33.PubMedCrossRefGoogle Scholar
  138. 138.
    Hu G, Qiao Q, Tuomilehto J, et al. Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. Diabetologia. 2004;47(7):1245–56.CrossRefGoogle Scholar
  139. 139.
    Resnick HE, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care. 2003;26(3):861–7.PubMedCrossRefGoogle Scholar
  140. 140.
    Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Wilson PW. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes. 2005;54(11):3252–7.PubMedCrossRefGoogle Scholar
  141. 141.
    Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation. 1998;97(10):996–1001.PubMedCrossRefGoogle Scholar
  142. 142.
    Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 1997;20(6):935–42.PubMedCrossRefGoogle Scholar
  143. 143.
    Folsom AR, Rasmussen ML, Chambless LE, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care. 1999;22(7):1077–83.PubMedCrossRefGoogle Scholar
  144. 144.
    Pyörälä M, Miettinen H, Laakso M, Pyörälä K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation. 1998;98(5):398–404.PubMedCrossRefGoogle Scholar
  145. 145.
    Yarnell JW, Patterson CC, Bainton D, Sweetnam PM. Is metabolic syndrome a discrete entity in the general population? Evidence from the Caerphilly and Speedwell population studies. Heart. 1998;79(3):248–52.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Pyörälä M, Miettinen H, Laakso M, Pyörälä K. Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Stroke. 1998;29(9):1860–6.PubMedCrossRefGoogle Scholar
  147. 147.
    Welin L, Bresäter LE, Eriksson H, Hansson PO, Welin C, Rosengren A. Insulin resistance and other risk factors for coronary heart disease in elderly men. The Study of Men Born in 1913 and 1923. Eur J Cardiovasc Prev Rehabil. 2003;10(4):283–8.PubMedCrossRefGoogle Scholar
  148. 148.
    Sarwar N, Sattar N, Gudnason V, Danesh J. Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies. Eur Heart J. 2007;28(20):2491–7.PubMedCrossRefGoogle Scholar
  149. 149.
    Chen W, Srinivasan SR, Li S, Xu J, Berenson GS. Metabolic syndrome variables at low levels in childhood are beneficially associated with adulthood cardiovascular risk: the Bogalusa Heart Study. Diabetes Care. 2005;28(1):126–31.PubMedCrossRefGoogle Scholar
  150. 150.
    Modan M, Halkin H, Almog S, et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest. 1985;75(3):809–17.PubMedPubMedCentralCrossRefGoogle Scholar
  151. 151.
    Reaven GM, Lerner RL, Stern MP, Farquhar JW. Role of insulin in endogenous hypertriglyceridemia. J Clin Invest. 1967;46(11):1756–67.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Jeppesen J, Hollenbeck CB, Zhou MY, et al. Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity, and postprandial lipemia. Arterioscler Thromb Vasc Biol. 1995;15(3):320–4.PubMedCrossRefGoogle Scholar
  153. 153.
    Tobey TA, Greenfield M, Kraemer F, Reaven GM. Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics, and plasma triglyceride levels in normotriglyceridemic man. Metabolism. 1981;30(2):165–71.PubMedCrossRefGoogle Scholar
  154. 154.
    Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med. 1989;320(11):702–6.PubMedCrossRefGoogle Scholar
  155. 155.
    Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–28.PubMedCrossRefGoogle Scholar
  156. 156.
    Reaven GM. The individual components of the metabolic syndrome: is there a raison d’etre? J Am Coll Nutr. 2007;26(3):191–5.PubMedCrossRefGoogle Scholar
  157. 157.
    Expert Panel on Detection Ea, Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–97.CrossRefGoogle Scholar
  158. 158.
    Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.PubMedCrossRefGoogle Scholar
  159. 159.
    Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16(5):442–3.PubMedCrossRefGoogle Scholar
  160. 160.
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53.PubMedCrossRefGoogle Scholar
  161. 161.
    Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9(3):237–52.PubMedGoogle Scholar
  162. 162.
    Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol. 2005;4(4):198–203.PubMedCrossRefGoogle Scholar
  163. 163.
    Alberti KG, Zimmet P, Shaw J. Metabolic syndrome –a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469–80.PubMedCrossRefGoogle Scholar
  164. 164.
    Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28(11):2745–9.PubMedCrossRefGoogle Scholar
  165. 165.
    Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S Adults. Diabetes Care. 2004;27(10):2444–9.PubMedCrossRefGoogle Scholar
  166. 166.
    Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38–60.PubMedCrossRefGoogle Scholar
  167. 167.
    Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010. J Am Coll Cardiol. 2013;62(8):697–703.PubMedPubMedCentralCrossRefGoogle Scholar
  168. 168.
    Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167(10):1068–74.PubMedCrossRefGoogle Scholar
  169. 169.
    Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program – Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30(1):8–13.PubMedCrossRefGoogle Scholar
  170. 170.
    Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112(20):3066–72.PubMedCrossRefGoogle Scholar
  171. 171.
    Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care. 2008;31(9):1898–904.PubMedPubMedCentralCrossRefGoogle Scholar
  172. 172.
    Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28(7):1769–78.PubMedCrossRefGoogle Scholar
  173. 173.
    Wang J, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J. 2007;28(7):857–64.PubMedCrossRefGoogle Scholar
  174. 174.
    Nilsson PM, Engström G, Hedblad B. The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects – a population-based study comparing three different definitions. Diabet Med. 2007;24(5):464–72.PubMedCrossRefGoogle Scholar
  175. 175.
    Katzmarzyk PT, Janssen I, Ross R, Church TS, Blair SN. The importance of waist circumference in the definition of metabolic syndrome: prospective analyses of mortality in men. Diabetes Care. 2006;29(2):404–9.PubMedCrossRefGoogle Scholar
  176. 176.
    Qiao Q, Group DS. Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia. 2006;49(12):2837–46.PubMedCrossRefGoogle Scholar
  177. 177.
    Sattar N, McConnachie A, Shaper AG, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008;371(9628):1927–35.PubMedCrossRefGoogle Scholar
  178. 178.
    van Herpt TT, Dehghan A, van Hoek M, et al. The clinical value of metabolic syndrome and risks of cardiometabolic events and mortality in the elderly: the Rotterdam study. Cardiovasc Diabetol. 2016;15(1):69.PubMedPubMedCentralCrossRefGoogle Scholar
  179. 179.
    Guzder RN, Gatling W, Mullee MA, Byrne CD. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia. 2006;49(1):49–55.PubMedCrossRefGoogle Scholar
  180. 180.
    Bonora E, Targher G, Formentini G, et al. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med. 2004;21(1):52–8.PubMedCrossRefGoogle Scholar
  181. 181.
    Tong PC, Kong AP, So WY, et al. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program’s Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care. 2007;30(5):1206–11.PubMedCrossRefGoogle Scholar
  182. 182.
    Sone H, Mizuno S, Fujii H, et al. Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diabetes Care. 2005;28(6):1463–71.PubMedCrossRefGoogle Scholar
  183. 183.
    Bruno G, Merletti F, Biggeri A, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care. 2004;27(11):2689–94.PubMedCrossRefGoogle Scholar
  184. 184.
    Cull CA, Jensen CC, Retnakaran R, Holman RR. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation. 2007;116(19):2119–26.PubMedCrossRefGoogle Scholar
  185. 185.
    Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP, Study SAH. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110(10):1251–7.PubMedCrossRefGoogle Scholar
  186. 186.
    Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–50.PubMedCrossRefGoogle Scholar
  187. 187.
    Stern MP, Williams K, Hunt KJ. Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease. Atheroscler Suppl. 2005;6(2):3–6.PubMedCrossRefGoogle Scholar
  188. 188.
    Stern MP, Williams K, González-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004;27(11):2676–81.PubMedCrossRefGoogle Scholar
  189. 189.
    Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes. 2004;53(5):1195–200.PubMedCrossRefGoogle Scholar
  190. 190.
    Liao Y, Kwon S, Shaughnessy S, et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care. 2004;27(4):978–83.PubMedCrossRefGoogle Scholar
  191. 191.
    Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino RB, Wilson PW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007;30(5):1219–25.PubMedCrossRefGoogle Scholar
  192. 192.
    Reaven GM. The metabolic syndrome: time to get off the merry-go-round? J Intern Med. 2011;269(2):127–36.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.SUNY Downstate Medical CenterNew YorkUSA

Personalised recommendations